Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study

Marianne E. Pavel, John D. Hainsworth, Eric Baudin, Marc Peeters, Dieter Hörsch, Robert E. Winkler, Judith Klimovsky, David Lebwohl, Valentine Jehl, Edward M. Wolin, Kjell Öberg, Eric Van Cutsem, James C. Yao

Research output: Contribution to journal › Article › peer-review

876 Scopus citations

Fingerprint

Dive into the research topics of 'Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study'. Together they form a unique fingerprint.

Medicine & Life Sciences